Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 427

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 427
---

    235,239

    BALANCE AT DECEMBER 31, 2024
     
    96,900

    $
    10

    $
    5,738,924

    $
    (218
    )
     
    $
    (4,210,974
    )
     
    $
    1,527,742

See accompanying notes to consolidated financial statements.

F-6

Sarepta Therapeutics, Inc.

Consolidated Statements of Cash Flows

(in thousands)

    For the Year Ended December 31,

    2024

    2023

    2022

    Cash flows from operating activities:

    Net income (loss)
     
    $
    235,239

    $
    (535,977
    )
     
    $
    (703,488
    )

    Depreciation and amortization

    37,724

    44,397

    41,864

    Reduction in the carrying amounts of the right of use assets

    16,167

    14,495

    12,735

    Non-cash interest expense

    4,951

    5,156

    7,552

    Stock-based compensation

    184,300

    182,514

    233,018

    Accretion of investment discount, net

    (40,277
    )

    (46,176
    )

    (10,651
    )

    Non-cash termination charges

    62,747

    —

    —

    Non-cash change in the fair value of derivatives

    7,838

    1,200

    (6,700
    )

    Impairment of strategic investments

    —

    30,321

    2,575

    Loss on debt extinguishment

    —

    387,329

    125,441

    Gain from sale of Priority Review Voucher

    —

    (102,000
    )

    —

    Other

    2,130

    (1,163
    )

    11,778

    Changes in operating assets and liabilities, net:

    Increase in accounts receivable

    (201,661
    )

    (185,699
    )

    (61,638
    )

    (Increase) decrease in manufacturing-related deposits and prepaids